For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Pharmaceutical research company Pharmaxis (ASX: PXS) is pleased to announce positive results of its recently completed Phase II trial of Bronchitol® (mannitol) in children and adolescents with cystic fibrosis (CF). The trial, conducted across 39 global centres, met its primary endpoint and confirms that Bronchitol is efficacious in young patients, regardless of concomitant dornase alfa use.Read full media release - pdf
Bennelong Innovation Forum
Pharmaxis CEO Gary Phillips was a key speaker at the inaugural Bennelong Innovation Forum attended by the Minister for Health, Sussan Ley, at Macquarie University on 9 December.
Gary told an audience of more than 400 attendees how Pharmaxis has grown through innovation and partnering.
Pharmaxis CEO Gary Phillips speaks to The Australian about policy to support the commercialisation of biomedical research.Read full media release - pdf
Following Pharmaxis recent announcement of a successful phase 1 clinical trial of the drug it sold to Boehringer Ingelheim earlier this year, Pharmaxis chief executive officer Gary Phillips has been interviewed by several journalists and analysts. Those interviews currently available on the internet may be accessed from the following links.
Australian Financial Review (article):
ABC Online (article & interview):
CommSec TV - Executive Series
CommSec’s Tom Piotrowski speaks with Pharmaxis Limited (PXS) CEO, Gary Phillips about the company’s successful Phase 1 trial results for a drug which it has sold to Germany’s Boehringer Ingelheim.
Proactive Investors (interview):
Bioshares article published 25 September 2015:
Read also Pharmaxis latest Corporate SummaryRead full media release - pdf